 | |
| Clinical data | |
|---|---|
| Trade names | Flarex, Florate, Omnitrol |
| Other names | Oxylone acetate; 1-Dehydro-9α-fluoro-11β,17α-dihydroxy-6α-methylprogesterone 17α-acetate; 17α-Acetoxy-9α-fluoro-11β-hydroxy-6α-methylpregna-1,4-diene-3,20-dione |
| Drug class | Corticosteroid;Glucocorticoid;Progestogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.021.156 |
| Chemical and physical data | |
| Formula | C24H31FO5 |
| Molar mass | 418.505 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fluorometholone acetate, also known asoxylone acetate and sold under the brand namesFlarex,Florate, andOmnitrol, is asyntheticglucocorticoidcorticosteroid and acorticosteroid ester, as well as aprogestogen andprogestogen ester.[1][2][3][4]: 186 It is the C17α acetate ester offluorometholone.[1][2][3]
In addition to its potent corticosteroid activity, fluorometholone acetate is a progestogen.[4] It has been studied in the treatment ofbreast cancer in women and has been found to be effective, producing remission in about 20% of women with advanced breast cancer at anoral dosage of 50 mg/day.[4] However, it also produces severeCushing's syndrome-like symptoms likeplethora,moon face,glycosuria, markedweight gain,hypertension, andosteoporosis at this dosage due to its glucocorticoid activity.[4]
Oxylone acetate (progesterone, 1-dehydro-9-fluoro-11β,17-dihydroxy-6α-methyl-17-acetate, fluorometholone), another halogenated progesterone, has been studied in patients with breast cancer (Cooperative Breast Cancer Group, 1964). This compound, given at a dose level of 50 mg per day orally, was shown to produce remission in about 20 % of the patients with advanced breast cancer. Both of these progestational compounds possess corticoid activity, particularly oxylone acetate, which, in 50 mg doses, causes Cushingoid symptoms, hypertension, and osteoporosis. On withdrawal of the drug, vaginal bleeding occurs frequently. [...] Progesterone-like compounds with glucocorticoid activity, such as oxylone, induce severe Cushingoid symptoms such as plethora, moonface, glycosuria, marked weight gain, and hypertension, requiring discontinuation of the drug.
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
